Peter Gibson, Hunter Medical Research Institute, peter.gibson@newcastle.edu.au,asar@thoracic.org.au
The Australian Benralizumab Registry (the ABenRA) collects and reports on data from people with severe refractory eosinophilic asthma who receive benralizumab:
- As part of the PBS subsidised benralizumab treatment cycle, and the Pharmaceutical Benefits Scheme (PBS) Section 100 Special Authority Program, or
- For severe refractory eosinophilic asthma outside of the PBS restrictions.
The ABenRA provides a mechanism for sharing information which will help researchers and clinicians to better understand the use, efficacy, and safety associated with the treatment of severe asthma with benralizumab.
The aim of the registry is to assess the change in patient reported asthma related symptoms after enrolment in the benralizumab registry following initiation of benralizumab in a real-world setting in the full study population and pre-specified subgroups.
- Reported in Annual Report
- Reported in other public reports
- Shared with clinicians
- Shared with medical colleges
- Asthma Control Questionnaire (ACQ)
- Asthma Quality of Life Questionnaire (AQLQ)
Nil
https://www.thoracic.org.au/researchawards/asar-sites
New South Wales
- Concord Repatriation General Hospital
- John Hunter Hospital
- St George Specialist Centre
- St Vincent’s Clinic
- Westmead Hospital
- Woolcock Institute of Medical Research
Western Australia
- Fiona Stanley Hospital
Victoria
- Frankston Hospital
Queensland
- Princess Alexandra Hospital
South Australia
- Royal Adelaide Hospital